Biogenity ApS
Private limited companyCVR 39606925Aalborg ØstActive
Biogenity ApS is a private limited company, based in Aalborg Øst, active in research and experimental development on natural sciences and engineering, founded in 2018. Equity was negative at the end of 2025 (−DKK 190k). The company made a loss in both 2024 and 2025, most recently DKK 454k. 8 other companies in the database are registered at the same address.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Gross profit fell 27% (2024 → 2025), to DKK 1.4m.
- The loss grew: from DKK 343k to DKK 454k (2024 → 2025).
- Equity turned negative: −DKK 190k (2024 → 2025).
Employees
- 1 fewer employees than a year earlier: 6 (07/2026) against 7 (07/2025).
Registrations, last 24 months
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2020–2025 · amounts in DKK thousandEquity and net profit
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | −115 | 97 | 1,251 | 2,397 | 1,899 | 1,388 | −26.9% |
| Operating profit (EBIT) | −317 | −699 | −108 | 587 | −432 | −559 | −29.5% |
| Profit before tax | 92 | 151 | −137 | 577 | −442 | −582 | −31.9% |
| Net profit | 72 | 117 | −108 | 449 | −343 | −454 | −32.3% |
| Total assets | 323 | 502 | 650 | 1,481 | 1,054 | 1,762 | +67.1% |
| Equity | 133 | 250 | 143 | 607 | 264 | −190 | −172% |
| Liabilities | 188 | 252 | 508 | 874 | 790 | 1,951 | +146.9% |
| Cash and cash equivalents | 209 | 322 | 520 | 493 | 365 | 686 | +88.1% |
| Average number of employees | – | 3 | 5 | 5 | 6 | 4 | −33.3% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 190k at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 2 years in a row
Net result has been negative in 2024–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
6 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/07/2024 – 30/06/2025 | 22/12/2025 | The company | PDF not statedXBRL |
| 2024 | 01/07/2023 – 30/06/2024 | 22/12/2024 | The company | PDFXBRL |
| 2023 | 01/07/2022 – 30/06/2023 | 20/12/2023 | The company | PDFXBRL |
| 2022 | 01/07/2021 – 30/06/2022 | 03/10/2022 | The company | PDFXBRL |
| 2021 | 01/07/2020 – 30/06/2021 | 29/10/2021 | The company | PDFXBRL |
| 2020 | 01/07/2019 – 30/06/2020 | 11/09/2020 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 38,466of 69,742 Better than 45% | No. 63,512of 69,964 Better than 9% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 113of 323 Better than 65% | No. 230of 329 Better than 30% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 20,377of 33,588 Better than 39% | No. 29,971of 33,687 Better than 11% |
| All companies of type ApS66,508 companies in the comparison | No. 37,106of 66,379 Better than 44% | No. 59,894of 66,505 Better than 10% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Biogenity ApSDKK 1.4m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Biogenity ApS−DKK 454k
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Biogenity ApS−DKK 190k
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Biogenity ApS6
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- L.Loeb Holding ApS50%
- Kastaniegaard Holding ApS50%
Management
4 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Louis Loeb | Director | 30/05/2018 |
| Kenneth Kastaniegaard | CEO | 30/05/2018 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Kenneth Kastaniegaard | Board member | 30/05/2018 |
| Louis Loeb | Chair of the board | 20/12/2018 |
- Founders
- L.Loeb Holding ApS, Kastaniegaard Holding ApS, S.Buch Holding IVS
Former management (5)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Louis Loeb | Deputy chair | 30/05/2018 | 19/12/2018 |
| Søren Buch Jensen | Director | 30/05/2018 | 20/12/2018 |
| Søren Buch Jensen | Chair of the board | 30/05/2018 | 20/12/2018 |
| Søren Buch Jensen | Director | 01/04/2019 | 25/06/2019 |
| Søren Buch Jensen | Deputy chair | 01/04/2019 | 25/06/2019 |
Signing rule: Selskabet tegnes af direktionen i forening.
Address and production units
2 active production unitsNiels Jernes Vej 10
9220 Aalborg Øst
Aalborg Municipality · Postcode 9220
Other companies at the address (8)
- Elsevier A/SComputer programming activities
- Emd International A/SComputer programming activities
- Pdm Technology ApSComputer programming activities
- Yggdrasil Commodities ApSOffice administrative and support activities
- Novi A/SManagement of real estate on a contract basis
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Biogenity ApS | Niels Jernes Vej 10, 9220 Aalborg Øst | 3 | 1023659731 |
| IT Security Department | Galopbakken 42, 9230 Svenstrup J | – | 1026350243 |
Purpose
Selskabets formål er at fungere som dataanalysebureau for den farmaceutiske industri.
The purpose is quoted from the register in Danish.
Changes year by year
34 registered events20252 changesaccounts 1 · industry 1
- AccountsAnnual report for 2025 published
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20241 changeaccounts 1
- AccountsAnnual report for 2024 published
20231 changeaccounts 1
- AccountsAnnual report for 2023 published
20221 changeaccounts 1
- AccountsAnnual report for 2022 published
20212 changesaccounts 1 · address 1
- AccountsAnnual report for 2021 published
- AddressMoved to Niels Jernes Vej 10, 9220 Aalborg Øst
20202 changesaccounts 1 · address 1
- AccountsAnnual report for 2020 published
- AddressMoved to Niels Jernes Vej 10, 9220 Aalborg Øst
201910 changesname 1 · capital 1 · management 4 · ownership 3 · industry 1
- NameName changed from Biogenity IVS to Biogenity ApS
- CapitalShare capital changed from 3 DKK to 80,000 DKK
- ManagementSøren Buch Jensen stepped down as director
- ManagementSøren Buch Jensen stepped down as deputy chair
- OwnershipSBJensen Holding IVS is no longer registered as owner
- ManagementSøren Buch Jensen appointed director
- ManagementSøren Buch Jensen appointed deputy chair
- OwnershipSBJensen Holding IVS registered as owner (33.33%)
- IndustryIndustry changed to Forskning og eksperimentel udvikling indenfor bioteknologi (721100)
- OwnershipS.Buch Holding IVS is no longer registered as owner
201815 changesmanagement 10 · address 1 · founded 1 · ownership 3
- ManagementLouis Loeb appointed chair of the board
- ManagementSøren Buch Jensen stepped down as chair of the board
- ManagementSøren Buch Jensen stepped down as director
- ManagementLouis Loeb stepped down as deputy chair
- AddressMoved to Dalgasgade 19, 3, 9000 Aalborg
- FoundedRegistered as Biogenity IVS
- ManagementSøren Buch Jensen appointed chair of the board
- ManagementSøren Buch Jensen appointed director
- ManagementLouis Loeb appointed director
- ManagementKenneth Kastaniegaard appointed ceo
- ManagementKenneth Kastaniegaard appointed board member
- ManagementLouis Loeb appointed deputy chair
- OwnershipS.Buch Holding IVS registered as owner (33.33%)
- OwnershipL.Loeb Holding ApS registered as owner (50%)
- OwnershipKastaniegaard Holding ApS registered as owner (50%)
Related companies
Same industry in Aalborg
- MyDefence A/S115 employees
- Rohde & Schwarz Technology Center A/S58 employees
- Nanonord A/S33 employees
- Dnasense ApS12 employees
- Steeper Energy Technologies ApS7 employees
- AW Technologies ApS3 employees
Same people in management
- Omics Studio ApSvia Kenneth Kastaniegaard
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.